Papers by Kerstin Brismar
Bookmarks Related papers MentionsView impact
Acta Paediatrica, 2001
Patients with cystic fibrosis (CF) are underweight and growth retarded. This study tested the lin... more Patients with cystic fibrosis (CF) are underweight and growth retarded. This study tested the link between serum insulin‐like growth factor‐I (IGF‐I) and insulin‐like growth factor‐binding protein‐3 (IGFBP‐3) levels and body height, nutritional status, pulmonary function tests and activity of inflammation in 92 subjects with CF (age 2.1–18.8 y). It also analysed the effect of short‐term antibiotic treatment and hyperalimentation on IGF‐I and IGFBP‐3 levels in 33 subjects (age 3.6–33.7 y) on 41 occasions. Both IGF‐I (‐1.19 ±0.17 SD) and IGFBP‐3 levels (‐0.66 ±0.12 SD; both p 0.0001 vs 0) were decreased in cross‐sectional measurements. Their standardized values were inversely proportional to age (IGF‐I: r= ‐0.23, p= 0.03; IGFBP‐3: r= ‐0.29, p= 0.005) and positively correlated with SDS of height (IGF‐I: r= 0.40, p 0.0001; IGFBP‐3: r= 0.36, p= 0.0005) and of mid‐arm circumference (IGF‐I: r= 0.39, p= 0.0001; IGFBP‐3: r= 0.38, p= 0.0002), and with pulmonary function tests. After a short‐term course of intensive antibiotic therapy and hyperalimentation, IGF‐I normalized (from ‐0.66 ± 0.20 to 0.00 ± 0.25 SD; pľ 0 0001) and IGFBP‐3 increased (from ‐0.78 ± 0.15 to ‐0.53 ± 0.16 SD; p= 0.002). IGFBP‐3 correlated inversely with erythrocyte sedimentation rate (r= ‐0.40, p= 0.01).
Bookmarks Related papers MentionsView impact
PubMed, May 15, 1991
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
The American Journal of Medicine, Feb 1, 2006
Bookmarks Related papers MentionsView impact
Diabetologia, 2014
ABSTRACT Meeting Abstract: 600
Bookmarks Related papers MentionsView impact
24th Joint Meeting of the British Endocrine Societies, Mar 1, 2005
Bookmarks Related papers MentionsView impact
Metabolism-clinical and Experimental, Aug 1, 2017
Bookmarks Related papers MentionsView impact
15th International & 14th European Congress of Endocrinology, May 1, 2012
Bookmarks Related papers MentionsView impact
European Journal of Endocrinology, Aug 2, 1981
Bookmarks Related papers MentionsView impact
PubMed, Feb 8, 2016
Hyperhidrosis affects 2.8% of the population and has severe negative influence on life quality. T... more Hyperhidrosis affects 2.8% of the population and has severe negative influence on life quality. The disease is represented in many specialties but can unfortunately be incorrectly treated or not treated at all. Primary hyperhidrosis is the most common form. Secondary hyperhidrosis is most often excluded by a few anamnestic data. Botulinum toxin and anticholinergics are adequate treatment options when aluminium chloride is insufficient. This article describes the disease from the physician's as well as the patient's perspective. Furthermore, examination procedures and treatment procedures are presented.
Bookmarks Related papers MentionsView impact
PubMed, May 1, 1985
Bookmarks Related papers MentionsView impact
Diabetologia, 2008
Bookmarks Related papers MentionsView impact
Diabetic Medicine, Nov 1, 1996
Bookmarks Related papers MentionsView impact
PubMed, 1988
Robinson, I.C.A.F. and Clark, R.G. (National Institute for Medical Research, Mill Hill, London, U... more Robinson, I.C.A.F. and Clark, R.G. (National Institute for Medical Research, Mill Hill, London, UK). Growth promoting activity of IGF-I in the rat. Acta Paediatr Scand [Suppl] 347: 93, 1988. According to the original somatomedin hypothesis, GH promotes growth by generating ‘somatomedins’ or insulin-like growth factors (IGFs) in the liver. The advent of large amounts of IGF-I produced by recombinant DNA technology has now allowed testing of this hypothesis, by comparing the growth promoting activity of IGF-I and GH in three animal models of growth deficiency. When injected or infused subcutaneously, or infused intravenously, IGF-I is a weak growth promoter in the hypophysectomized rat compared with GH, even when infused in combination with small amounts of GH. Growth arrest in the diabetic rat was corrected by insulin infusion which also restored GH secretion. lnsulin or IGF-I caused a large initial weight gain in diabetic rats, accompanied by a partial correction of food and water balance, even in the presence of persistent hyperglycaemia. A new mutant GH deficient dwarf rat grows in response to both GH and IGF-I infusions, but these agents elicit different patterns of organ growth. For the same overall body growth, GH was more effective in stimulating bone growth, whereas IGF-I stimulated renal and splenic growth. This new dwarf rat may prove useful for the study of the relative growth promoting effects of IGF-I and GH in more detail in future.
Bookmarks Related papers MentionsView impact
PubMed, 2012
Evidence has recently indicated that the MRAS and HNF1A genetic polymorphisms are associated with... more Evidence has recently indicated that the MRAS and HNF1A genetic polymorphisms are associated with coronary artery disease. The MRAS and HNF1A genes are located on chromosomes 3q and 12q within the regions where associations with diabetes and diabetic nephropathy occur. We thus performed genetic and functional analyses of these two genes to evaluate their impacts on diabetes and diabetic nephropathy. MRAS and HNF1A genetic polymorphisms were genotyped in 1399 Czech subjects including non-diabetic controls (339), type 1 (243) and type 2 (817) diabetic patients with and without diabetic nephropathy using TaqMan allelic discrimination. Gene expression levels in the kidneys of diabetic Goto-Kakizaki and Wistar rats were detected with real-time RT-PCR. Despite no significance in genetic analysis of diabetic subjects, SNP rs2259816 in the HNF1A gene tended to associate with diabetic nephropathy in type 1 diabetic patients. The hnf1a gene expression was significantly decreased in kidney tissues of Goto-Kakizaki rats compared to Wistar and insulin-treated Goto-Kakizaki rats. There was neither significant association in the MRAS genetic polymorphism with diabetic nephropathy nor variation of mras gene expression in the kidneys of Goto-Kakizaki and Wistar rats. Data from the present study have not proved any significant association of the MRAS and HNF1A genetic polymorphisms with diabetes and diabetic nephropathy in a cohort of Czech population. However, the functional analysis and the trend in genetic analysis suggest that the HNF1A gene may have primary genetic impact on the development of diabetic nephropathy.
Bookmarks Related papers MentionsView impact
Journal of diabetes research, Jun 15, 2020
Bookmarks Related papers MentionsView impact
Maturitas, Aug 1, 2019
Bookmarks Related papers MentionsView impact
Adipocyte, Jan 8, 2016
Bookmarks Related papers MentionsView impact
Growth hormone & IGF research, Aug 1, 2016
INTRODUCTION Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein ... more INTRODUCTION Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 (IGFBP-1) play an important role in vascular health. Many patients with type 1 diabetes are medicated with HMG-CoA reductase inhibitors, statins, in order to prevent vascular complications. Yet little is known about the effect of statins on the IGF-1/IGFBP-1 axis in these patients. OBJECTIVES The aim of this study was to evaluate the effect of atorvastatin treatment on IGF-1 and IGFBP-1 with regards to microvascular function. DESIGN Twenty patients with type 1 diabetes received either placebo or 80mg atorvastatin for two months in a double-blinded cross-over study. IGF-1 and IGFBP-1 levels were assessed before and after each treatment period. Skin microcirculation was studied using Doppler perfusion imaging during iontophoresis of acetylcholine and sodium nitroprusside to assess endothelium-dependent and endothelium-independent microvascular reactivity, respectively. RESULTS Treatment with high-dose atorvastatin was associated with a significant decrease in IGF-1 levels compared to placebo (p<0.05, ANOVA repeated measures), whereas no effect was seen on IGFBP-1 or the IGF-1/IGFBP-1 ratio. These variables did not correlate with measurements of skin microvascular reactivity. CONCLUSIONS The study found that treatment with high-dose atorvastatin was associated with reduced IGF-1 levels, which may indicate a potential negative effect on microvascular function and long-term risk of microangiopathy development.
Bookmarks Related papers MentionsView impact
Uploads
Papers by Kerstin Brismar